SCHEMBL5266777

SCHEMBL5266777

Cc1ccc(O)c(-c2n[nH]c(C)c2C2=COC=C(C3=CC=CCC3)O2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 9/20 0.33
GAA P10253 3/20 0.33
ALDH1A1 P00352 1/20 0.33
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
HSP90AB1 P08238 1/20 0.32
MET P08581 1/20 0.32
PIM1 P11309 1/20 0.32
LTK P29376 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GPR55 Q9Y2T6 2/20 0.31
ALOX15 P16050 2/20 0.31
ALOX12 P18054 2/20 0.31
MAPK1 P28482 2/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
GYS1 P13807 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5272249 0.91 MEN1 (0.39) HSP90AA1GAAALDH1A1MEN1MAPT
SCHEMBL5273258 0.91 HSP90AA1 (0.34) HSP90AA1GAAALDH1A1MEN1MAPT
SCHEMBL5271929 0.88 HSP90AA1 (0.47) HSP90AA1GAAMEN1MAPTKMT2A
SCHEMBL5269354 0.86 HSP90AA1 (0.48) HSP90AA1GAAALDH1A1MEN1MAPT
SCHEMBL5267152 0.83 HSP90AA1 (0.38) HSP90AA1GAAALDH1A1MEN1MAPT
SCHEMBL5274678 0.79 HSP90AA1 (0.33) HSP90AA1MEN1KMT2A
SCHEMBL5267956 0.76 LRRK2 (0.41)
SCHEMBL5268022 0.76 CHEK1 (0.31)
SCHEMBL5273461 0.75 MET (0.35) METHTT
SCHEMBL5269715 0.75 LRRK2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885GAA 4306/4885ALDH1A1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.